Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.
Saved in:
| Title: | Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. |
|---|---|
| Authors: | Grinda T; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Gustave Roussy, Medical Oncology Department, Villejuif, France., Heiling HM; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Tayob N; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Smith KL; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Davis R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cotter C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., DeMeo MK; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Santa-Maria CA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Van Poznak C; University of Michigan, Ann Arbor, MI, USA., Moy B; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA., Brufsky AM; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Melisko ME; University of California at San Francisco, San Francisco, CA, USA., O'Sullivan CC; Mayo Clinic, Rochester, MN, USA., Isaacs C; MedStar/Georgetown University, Washington, DC, USA., Rauf Y; University of North Carolina, Chapel Hill, NC, USA., Nangia JR; Baylor College of Medicine, Houston, TX, USA., Burns RT; The Emmes Corporation, Rockville, MD, USA., Savoie J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Emmes Corporation, Rockville, MD, USA., Wolff AC; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Winer EP; Yale Cancer Center, New Haven, CT, USA., Mayer EL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Rimawi MF; Baylor College of Medicine, Houston, TX, USA., Ruddy KJ; Mayo Clinic, Rochester, MN, USA., Rocque G; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA., Krop IE; Yale Cancer Center, New Haven, CT, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Freedman RA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rachel_freedman@dfci.harvard.edu. |
| Source: | Breast (Edinburgh, Scotland) [Breast] 2026 Jul 20; Vol. 89, pp. 104881. Date of Electronic Publication: 2026 Jul 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
